Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients

Liu, Chao; Wang, Wei; Meng, Xiao; Sun, Bing; Cong, Yang; Liu, Jiannan; Wang, Qian; Liu, Guangxian; Wu, Shikai

doi:10.2147/ott.s159481

“…Several recent studies have shown that systemic inflammation plays an important role in tumorigenesis and disease progression, suggesting the potential utility of inflammation as a prognostic marker. 8 , 9 , 16 , 33 – 35 Tumor-related inflammatory markers include biochemical and hematological indicators such as CA125, and leukocyte, neutrophil, and platelet cell count. Among them, neutrophils promote tumor development by remodeling the extracellular matrix and releasing ROS, nitric oxide, and arginase.…”

Section: Discussionmentioning

confidence: 99%

Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapy

Li¹,

Shao²,

Bai³

et al. 2018

CMAR

View full text Add to dashboard Cite

IntroductionThe prognostic role of the derived neutrophil-to-lymphocyte ratio (dNLR) in human patients with HER2+ breast cancer is not well understood. Here, we aimed to investigate the prognostic significance of dNLR in patients with HER2+ breast cancer undergoing neoadjuvant chemotherapy.MethodsA total of 310 patients with non-distant metastatic HER2+ breast cancer who had received neoadjuvant chemotherapy in our hospital from May 2006 to November 2013 were retrospectively included in this study. Kaplan–Meier curves were used to assess overall survival (OS) and disease-free survival (DFS). The Cox regression model was used to evaluate the prognostic value of dNLR and Breast Imaging-Reporting and Data System (BI-RADS) classification, as well as other clinicopathological parameters in patients with HER2+ breast cancer treated with neoadjuvant chemotherapy.ResultsWe found that dNLR prior to treatment was positively correlated with tumor size, tumor stage, lymphovascular invasion, and histological grade (P<0.05). The median OS of patients with high dNLR and low dNLR were 44.2 and 69.9, respectively (P<0.001), and the median DFS of patients with high dNLR and low dNLR were 15.3 and 22.1 months, respectively (P<0.001). Multivariate analysis showed that dNLR was an independent risk factor for OS (HR =1.726; 95% CI: 1.072–2.662; P=0.009) and DFS (HR =1.658; 95% CI: 1.125–2.426; P=0.026). Moreover, increased BI-RADS classification independently predicted short OS (HR =1.609; 95% CI: 1.216–2.351; P=0.015) and DFS (HR =1.925; 95% CI: 1.526–2.635; P=0.021).ConclusiondNLR prior to treatment and BI-RADS classification are independent prognostic factors in patients with HER2+ breast cancer receiving neoadjuvant chemotherapy.

show abstract

“…Previous studies have provided results indicating that AGR may be an independent prognostic indicator in patients with cancer cachexia ( 39 ), and that AGR exhibits prognostic significance in metastatic prostate ( 40 ), rectal ( 41 ), gastric ( 15 ), cervical ( 42 ) and nasopharyngeal cancer ( 43 ). Furthermore, Liu et al ( 44 ) demonstrated that AGR affects the PD-1/PD-L1 pathway in breast cancer, with implications for immunotherapy. Notably, the present study indicated that treatment progression may contribute to a reduction in AGR, and that patients with a high AGR exhibited higher ORR and DCR than those with a low AGR.…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood nutrient indices as biomarkers for anti‑PD‑1 therapy efficacy and prognosis in patients with advanced gastric cancer

Wang

¹

,

Liu

²

,

Dai

³

et al. 2023

Oncol Lett

5

0

View full text Add to dashboard Cite

Immunotherapy offers survival benefits for patients with advanced gastric cancer, but not all populations can benefit from immunotherapy. Good nutritional status is fundamental to a patient's immune function and may have an impact on the efficacy of immunotherapy. The present study aimed to investigate changes in prognostic nutritional index (PNI), advanced lung cancer inflammation index (ALI) and albumin-globulin ratio (AGR) values before and after immunotherapy in patients with advanced gastric cancer. The study also aimed to determine the potential association of the aforementioned values with patient outcomes and prognosis. Body mass index (BMI), serum albumin, total protein, peripheral blood lymphocyte, neutrophil, carcinoembryonic antigen (CEA), carbohydrate antigen19-9 (CA19-9) and a-fetoprotein (AFP) data were collected from 195 patients with advanced gastric cancer who underwent immunotherapy from January 2020 to October 2021. In addition, PNI, ALI and AGR values were calculated based on variables in blood collected from the patients within 3 days prior to immunotherapy and 3 weeks after immunotherapy. The results demonstrated that low PNI was associated with elevated CEA levels. Moreover, low ALI levels were associated with reduced BMI levels, elevated AFP levels, PD-L1 negative and first-line treatment. Comparison of responding and non-responding groups revealed that patients who responded to immunotherapy had higher PNI and AGR values than patients who did not respond, both before and after treatment, but had lower CEA and CA19-9 levels after treatment. Furthermore, in the non-responding group, PNI and AGR values were decreased and CEA values were increased following treatment compared with those prior to treatment. The objective response and disease control rates were higher in the high PNI and AGR groups compared with the low PNI and AGR groups, respectively. Moreover, PNI and AGR were found to be independent predictors of the short-term efficacy of immunotherapy for advanced gastric cancer, with cut-off values of 47.18 and 1.29, respectively. Univariate analysis revealed that ALI was associated with the progression-free survival (PFS) of patients, while multivariate analysis demonstrated that baseline PNI and AGR were independent predictors of PFS. In conclusion, tumor progression leads to a decline in the nutritional level of patients, and the present study indicated that effective immunotherapy may alleviate this deterioration to a certain extent. Furthermore, PNI and AGR exhibit potential in predicting the efficacy of immunotherapy and the prognosis of patients with advanced gastric cancer, and may exhibit potential as biomarkers in clinical practice.

show abstract

“…The CREAT-X trial's findings demonstrated that adjuvant capecitabine therapy could considerably increase OS and DFS in HER-2-negative breast cancer patients who did not achieve a pCR following NAC, with the TNBC group benefiting the most [7]. The KATHERINE study revealed that the 3-year invasive disease-free survival (iDFS) rate of T-DM1 was considerably higher than that of the trastuzumab group for patients who did not achieve a pCR following 6-8 cycles of neoadjuvant therapy [8]. Although the above drugs have improved the prognosis of breast cancer patients with a nonpCR, it is worth considering screening out patients with poor responses to NAC and the standard adjuvant therapy agents and implementing different treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have recently examined the relationships among inflammation, nutrition, and malignant tumors [11]. Different inflammatory and nutritional parameters, such as body mass index (BMI), prognostic nutrition index (PNI), albumin to globulin ratio (AGR), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), as well as their combinations, have all been shown to be vital predictors for breast cancer patients [7][8][9][10][12][13][14][15]. However, a single variable can only provide limited information.…”

Section: Introductionmentioning

confidence: 99%

A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Jiang

¹

,

Xiu

²

,

Zhang

³

et al. 2022

View full text Add to dashboard Cite

Background. It has been demonstrated that inflammatory and nutritional variables are associated with poor breast cancer survival. However, some studies do not include these variables due to missing data. To investigate the predictive potential of the INPS, we constructed a novel inflammatory-nutritional prognostic scoring (INPS) system with machine learning. Methods. This retrospective analysis included 249 patients with malignant breast tumors undergoing neoadjuvant chemotherapy (NAC). After comparing seven potent machine learning models, the best model, Xgboost, was applied to construct an INPS system. K-M survival curves and the log-rank test were employed to determine OS and DFS. Univariate and multivariate analyses were carried out with the Cox regression model. Additionally, we compared the predictive power of INPS, inflammatory, and standard nutritional variables using the Z test. Results. After comparing seven machine learning models, it was determined that the XGBoost model had the best OS and DFS performance ( AUC = 0.865 and 0.771 , respectively). For overall survival (OS, cutoff value = 0.3917 ) and disease-free survival ( cutoff value = 0.4896 ), all patients were divided into two groups by the INPS. Those with low INPS had higher 5-year OS and DFS rates (77.2% vs. 50.0%, P < 0.0001 ; and 59.6% vs. 32.1%, P < 0.0001 , respectively) than patients with high INPS. For OS and DFS, the INPS exhibited the highest AUC compared to the other inflammatory and nutritional variables ( AUC = 0.615 , P = 0.0003 ; AUC = 0.596 , P = 0.0003 , respectively). Conclusion. The INPS was an independent predictor of OS and DFS and exhibited better predictive ability than BMI, PNI, and MLR. For patients undergoing NAC for nonpCR breast cancer, INPS was a crucial and comprehensive biomarker. It could also forecast individual survival in breast cancer patients with low HER-2 expression.

show abstract

Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients

Cited by 11 publications

References 49 publications

Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapy

Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapy

Peripheral blood nutrient indices as biomarkers for anti‑PD‑1 therapy efficacy and prognosis in patients with advanced gastric cancer

A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Contact Info

Product

Resources

About